Updated:
Injective Labs Inc.
Injective Labs builds the Injective blockchain for decentralized finance, operating from Dublin, Hong Kong, Singapore, and New York.
Injective Labs Inc.
Injective Labs was founded by Eric Chen and Albert Chon, who previously worked at leading blockchain projects. The firm's wealth origin is not publicly disclosed, but it has raised venture funding from investors including Pantera Capital, Binance Labs, and Mark Cuban. The company develops the Injective Protocol, a blockchain optimized for decentralized derivatives and spot trading. The firm's core product is the Injective chain, which uses Tendermint consensus and supports interoperability with Ethereum, Cosmos, and other blockchains via IBC bridges. Injective Labs earns revenue from transaction fees on the network and provides development tools for building DeFi applications. The protocol enables perpetual swaps, futures, and options trading without centralized order books. Injective Labs employs a team of blockchain engineers and cryptographers distributed across its four office locations. The company has not disclosed total assets under management or deployment figures, as it operates primarily as a technology development entity rather than an investment fund. In 2023, Injective Protocol launched its mainnet and has since processed over $1 billion in cumulative trading volume (per CoinDesk, 2023). The firm's structural differentiator is its focus on building a sovereign blockchain specifically for DeFi, rather than launching on existing platforms like Ethereum. This approach gives Injective Labs control over protocol parameters and fee structures, allowing customization for institutional-grade trading features.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Ireland
City
Dublin
Corporate office
Dublin, Ireland
Additional offices
Hong Kong · Singapore · New York, United States
Sector focus
Frequently asked questions
Who leads Injective Labs?
Injective Labs was co-founded by Eric Chen (CEO) and Albert Chon (CTO). Chen previously led product at a blockchain startup, and Chon has a background in cryptography and distributed systems. The founding team is central to the firm's technical roadmap.
How does Injective Labs source its revenue?
The firm earns transaction fees from the Injective blockchain network. It also provides development and consulting services for projects building on the protocol.
Is Injective Labs a family office or an investment firm?
Injective Labs is a technology development company that builds and maintains the Injective blockchain. It is not structured as a family office or traditional investment firm.
What investment stages does Injective Labs target?
Injective Labs does not operate as an investment fund. It focuses on protocol development and ecosystem growth through its own treasury and grant programs.
Which sectors does Injective Labs focus on?
The firm's primary focus is blockchain infrastructure and decentralized finance (DeFi), including derivatives trading, cross-chain interoperability, and DeFi applications.
How is Injective Labs related to the Injective Protocol?
Injective Labs is the primary development company behind the Injective Protocol, a layer-1 blockchain. The firm maintains the protocol's codebase and supports its governance.
Does Injective Labs have any operating companies or foundations?
Yes, the Injective Protocol is governed by the Injective Foundation. The foundation manages grants and community initiatives, separate from Injective Labs' development operations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: